Supply Chain Intelligence

Vera Therapeutics, Inc. Supply Chain

VERA supply chain intelligence for Vera Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

VERA ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

13Suppliers
0Customers
2Debt Items
20Related Chains

Vera Therapeutics, Inc. Suppliers

TickerNameConfidenceEvidence
ARES-TRADING-S-A ARES-TRADING-S-A 90% If we breach our license agreement (Ares Agreement) with Ares Trading S.A. (Ares), an affiliate of Merck KGaA, Darmstadt, Germany, related to atacicept, or the license agreement with Novartis Interna…
BOARD-OF-TRUSTEES-OF-LELAND-STANFORD-JUNIOR-UNIV BOARD-OF-TRUSTEES-OF-LELAND-STANFORD-JUNIOR-UNIV 90% If we breach our license agreement (Ares Agreement) with Ares Trading S.A. (Ares), an affiliate of Merck KGaA, Darmstadt, Germany, related to atacicept, or the license agreement with Novartis Interna…
NOVARTIS-INTERNATIONAL-PHARMACEUTICAL-AG NOVARTIS-INTERNATIONAL-PHARMACEUTICAL-AG 90% If we breach our license agreement (Ares Agreement) with Ares Trading S.A. (Ares), an affiliate of Merck KGaA, Darmstadt, Germany, related to atacicept, or the license agreement with Novartis Interna…
OFCF-II OFCF-II 90% The Company accounted for the loan syndicate on a creditor-by-creditor basis. With respect to the continuing creditors, Oxford Finance, OFCF II, and OFCF III, the Company accounted for this transacti…
OFCF-III OFCF-III 90% The Company accounted for the loan syndicate on a creditor-by-creditor basis. With respect to the continuing creditors, Oxford Finance, OFCF II, and OFCF III, the Company accounted for this transacti…
OFCF-IV OFCF-IV 90% With respect to the new lender, OFCF IV, the Company accounted for this transaction as an issuance of debt
OXFORD-FINANCE OXFORD-FINANCE 90% The Company accounted for the loan syndicate on a creditor-by-creditor basis. With respect to the continuing creditors, Oxford Finance, OFCF II, and OFCF III, the Company accounted for this transacti…
AUPH Aurinia Pharmaceuticals Inc. 72% experienced any significant delays in obtaining any raw materials from our suppliers, we cannot provide assurance that we will not face shortages from one or more of them in the future. Please see th…
AUPH Aurinia Pharmaceuticals Inc. 72% Reciprocal relationship from AUPH graph: Reciprocal relationship from VERA graph: Reciprocal relationship from AUPH graph: Reciprocal relationship from VERA graph: Reciprocal relationship from AUPH g…
SNYNF Sanofi 72% experienced any significant delays in obtaining any raw materials from our suppliers, we cannot provide assurance that we will not face shortages from one or more of them in the future. Please see th…
SNYNF Sanofi 72% Reciprocal relationship from SNYNF graph: Reciprocal relationship from VERA graph: experienced any significant delays in obtaining any raw materials from our suppliers, we cannot provide assurance th…
TVTX Travere Therapeutics, Inc. 72% Reciprocal relationship from TVTX graph: Reciprocal relationship from VERA graph: Reciprocal relationship from TVTX graph: Reciprocal relationship from VERA graph: experienced any significant delays …
TVTX Travere Therapeutics, Inc. 72% experienced any significant delays in obtaining any raw materials from our suppliers, we cannot provide assurance that we will not face shortages from one or more of them in the future. Please see th…

Vera Therapeutics, Inc. Customers

No clients on recordNo downstream customers found in our database for Vera Therapeutics, Inc..

Vera Therapeutics, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
VERA-DEBT-13326 Xbrl Convertible 90% xbrl convertible detail from xbrl 2021-12-31.
VERA-DEBT Debt stack $76.9M 90% Market cache reports total debt of $76.9M.

Vera Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Vera Therapeutics, Inc..

Vera Therapeutics, Inc. Ownership

HolderNameConfidenceEvidence
VERA-OWNER-AVORO-CAPITAL-ADVISORS-LLC Avoro Capital Advisors LLC 90% 13F overlay lists Avoro Capital Advisors LLC as top holder; 232 tracked holders.

Vera Therapeutics, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
DBVTF DBV TECHNOLOGIES 100.00 2
EDIT Editas Medicine, Inc. 100.00 2
DSGN Design Therapeutics, Inc. 100.00 2
CSLLY CSL Limited 100.00 2
WHWK Whitehawk Therapeutics, Inc. 100.00 2
AZN AstraZeneca PLC 100.00 2
CTNM Contineum Therapeutics, Inc. 100.00 2
BLRX BioLineRx Ltd. 100.00 2
CLYM Climb Bio, Inc. 100.00 1 ['spend']
ANRO Alto Neuroscience, Inc. 100.00 2
CYTOF Altamira Therapeutics Ltd. 100.00 2
BNBX BNB Plus Corp. 100.00 2
CTMX CytomX Therapeutics, Inc. 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
CYTK Cytokinetics, Incorporated 100.00 2
CBIO Crescent Biopharma, Inc. 100.00 2
ANL Adlai Nortye Ltd. 100.00 2
ALXO ALX Oncology Holdings Inc. 100.00 2
CCEP Coca-Cola Europacific Partners PLC 100.00 2
ATOS Atossa Therapeutics, Inc. 100.00 2
View VERA supply chain intel →

Explore the full interactive supply chain map for Vera Therapeutics, Inc..

Open VERA supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map